Teena Thacker's profile photo

Teena Thacker

Delhi

Journalist at The Economic Times

Journalist @EconomicTimes |#pharma| #health. Awarded: #RamnathGoenka| #CJEA| @Laadli_PF. Ex @livemint| @IndianExpress|Tweets r personal,RTs ≠endorsements

Articles

  • 5 days ago | economictimes.indiatimes.com | Teena Thacker

    The new data from the country's official record of births and deaths that suggests undercounting of deaths during the pandemic has given a ray of hope to the parents of children who may have died due to the side effects of Covid vaccine.The parents, who are fighting a legal battle, will use the government data in the court, they said.According to the data from the Civil Registration System (CRS), about 2.1 million more deaths were registered in 2021 - the year that witnessed the deadly Delta...

  • 1 week ago | economictimes.indiatimes.com | Teena Thacker

    Amid escalating India-Pakistan tensions , Union health minister J P Nadda chaired a high-level meeting to review emergency health systems preparedness.The ministry has directed that a 24x7 control and command centre in the ministry should monitor ongoing efforts and support states in the present timesIn a meeting held today with the senior officers of the health ministry, Nadda reviewed the current status of medical preparedness for handling emergency cases.“He was apprised of the actions...

  • 1 week ago | economictimes.indiatimes.com | Teena Thacker

    India's pharma industry is likely to see a sharp increase in the number of surprise inspections by the US Food and Drug Administration (FDA) after President Donald Trump signed an executive order seeking closer scrutiny of overseas plants by the US drug regulator.Marty Makary, commissioner, US Food and Drug Administration (FDA), said as much on Monday.

  • 1 week ago | economictimes.indiatimes.com | Teena Thacker |Vikas Dandekar

    • Minimising use of animals in testing The government is giving final touches to a revised set of regulations to set stringent quality standards for research and manufacture of biosimilar drugs , which are emerging as a mainstay for treatment of cancers and autoimmune diseases among others.Biosimilars are medicines based on living cells and are very similar—but not identical—to originally invented biological drugs, or biologics.Currently under consultations, the ‘Guidelines on Similar...

  • 2 weeks ago | economictimes.indiatimes.com | Teena Thacker

    The government is considering bringing the controversial opioid Tapentadol under the Narcotic Drugs and Psychotropic Substances (NDPS) Act following allegations of unbridled exports of the drug to West African nations causing an opioid addiction crisis there.The move is expected to substantially reduce Tapentadol's availability through tight regulation, including oversight on its movement by the Narcotics Control Bureau NCB ) and police.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers
24K
Tweets
15K
DMs Open
No
Teena Thacker
Teena Thacker @Teensthack
7 May 25

RT @Balkris46773410: Biosimilars are biologic medications that are highly similar to an already approved biologic,meaning they have no clin…

Teena Thacker
Teena Thacker @Teensthack
7 May 25

Trump's prescription: Indian drug units may face stricter check-ups - The Economic Times https://t.co/PKK3RfsfCs

Teena Thacker
Teena Thacker @Teensthack
6 May 25

RT @kiranshaw: India must consider adopting innovative methods such as organoids, in vitro, and in-silico methods as part of regulatory ref…